Patent ID: 8865663
Filing Date: 2014-10-21
Classification: A61K,A61P,C07K,G01N,G16H

Abstract:
1. A method of treating cancer which is negative for expression of both an Estrogen Receptor (ER) and a Human Epidermal Growth Factor Receptor-2 (HER-2), comprising: first determining that the cancer is negative for expression of ER, and negative for expression of HER2; second performing a docetaxel administration cycle consisting of administrating docetaxel to a patient multiple times at certain intervals; and then third performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals.